drugset / Trial / NCT07246785

Anrikefon-based Patient-controlled Intravenous Analgesia After Laparoscopic Surgery

NCT07246785 ↗

Phase 4 Terminated 13 enrolled Peking University First Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Visceral pain following laparoscopic surgery is frequently underestimated, yet it is associated with a range of adverse outcomes. Effective visceral pain management should constitute an essential component of postoperative analgesic strategies following laparoscopic procedures. However, conventional analgesic agents, including μ-opioid receptor agonists, lack specificity for visceral pain. Anrikefon, a novel selective peripheral κ-opioid receptor agonist, demonstrates unique efficacy in alleviating visceral pain with a favorable safety profile. Preliminary studies showed that a single intravenous dose of anrikefon effectively alleviates postoperative pain after abdominal surgery with a low risk of adverse effects. The investigators hypothesize that an appropriate dosing regimen of anrikefon administered via patient-controlled intravenous analgesia (PCIA) pump, as part of a multimodal analgesic strategy, can specifically target and alleviate visceral pain after laparoscopic surgery, thereby achieving comprehensive postoperative analgesia.

Timeline

Start
2025-12-25
Primary completion
2026-02-11
Completion
2026-03-11

Outcome

Outcome not reported

Stopped: “The study was terminated due to substantial protocol amendments involving changes in the target population and primary endpoint, rendering previously collected data incompatible with the revised study objective.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anrikefon Unknown 5 ug/ml Intravenous
Subject Anrikefon Unknown 7.5 ug/ml Intravenous
Subject Anrikefon Unknown 10 ug/ml Intravenous
Comparator Morphine Other / unclassified 0.5 mg/ml Intravenous

Indications

No indication recorded.